{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:42:35Z","timestamp":1790613755780,"version":"4.1.0"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82560541"],"award-info":[{"award-number":["82560541"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human papillomavirus (HPV) vaccination is a cornerstone of global strategies to prevent HPV-associated malignancies; however, uncertainties persist regarding its long-term efficacy, immunogenicity, and safety across populations, vaccine formulations, and dosing schedules. We conducted a comprehensive systematic review and meta-analysis to evaluate the clinical and immunological effectiveness of prophylactic HPV vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study followed PRISMA guidelines and was registered in PROSPERO (CRD420251050526). Randomized controlled trials (RCTs) were identified through comprehensive searches of six major databases. Risk of bias was assessed using the RoB 2 tool. Meta-analyses were performed using random- or fixed-effects models as appropriate. Subgroup and meta-regression analyses explored the effects of age, sex, vaccine type, dosing regimen, and HIV status. Certainty of evidence was appraised using the GRADE framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 145 RCTs were included. HPV vaccination significantly reduced cervical intraepithelial neoplasia grade 1 (RR = 0.15, 95% CI: 0.09\u20130.24), grade 2 (0.20, 0.13\u20130.30), and grade 3 (0.48, 0.23\u20130.98). Persistent HPV16\/18 infections were reduced by 84% (0.16, 0.12\u20130.21), and incident infections by 75% (0.25, 0.19\u20130.34). Immunogenicity analyses demonstrated robust antibody responses, with fold increases of 3.09 for HPV16, 3.10 for HPV18, 3.48 for HPV6, and 3.37 for HPV11. Tissue-resident CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells were significantly reduced (SMD: \u22121.27, 95% CI: \u22122.24 to \u22120.31), while CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells showed no significant change. Vaccination was not associated with an increased risk of serious adverse events (0.90, 0.82\u20130.99) or adverse pregnancy outcomes. Although, injection-site adverse events were modestly increased (1.26, 1.07\u20131.48).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prophylactic HPV vaccination provides strong protection against HPV infections and precancerous lesions and induces robust humoral immunity with a favorable safety profile. The nonavalent vaccine, particularly when administered in a three-dose (0\/1\/6) regimen, offers the most comprehensive protection. These findings support the expansion of gender-neutral vaccination programs to maximize population-level cancer prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251050526.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1747082","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:35:06Z","timestamp":1768286106000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Comprehensive evaluation of prophylactic HPV vaccines: a systematic review and meta-analysis of efficacy, safety, and immunogenicity in males and females"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhiliang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanli","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1051\/bioconf\/20248601029","article-title":"Unravelling the impact of human papillomavirus (HPV): a comprehensive exploration of its role in cancer progression and global health challenges","author":"Potale","year":"2024"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3390\/vaccines12111293","article-title":"Human papillomavirus (HPV) vaccination: progress, challenges, and future directions in global immunization strategies","volume":"12","author":"Branda","year":"2024","journal-title":"Vaccines"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1908059","DOI":"10.1080\/21645515.2021.1908059","article-title":"Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge","volume":"18","author":"Hoes","year":"2022","journal-title":"Hum Vaccines immunotherapeutics"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013479","article-title":"Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males","volume":"2019","author":"Bergman","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"Cd009069","DOI":"10.1002\/14651858.CD009069.pub3","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","volume":"5","author":"Arbyn","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4954","DOI":"10.1038\/s41598-021-83727-7","article-title":"Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis","volume":"11","author":"Zizza","year":"2021","journal-title":"Sci Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101585","article-title":"Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis","volume":"52","author":"Staadegaard","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.07.055","article-title":"Prophylactic HPV vaccination after conization: A systematic review and meta-analysis","volume":"38","author":"Jentschke","year":"2020","journal-title":"Vaccine"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070135","article-title":"Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis","volume":"378","author":"Kechagias","year":"2022","journal-title":"bmj"},{"key":"B10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/vaccines10020239","article-title":"HPV vaccination after primary treatment of HPV-related disease across different organ sites: a multidisciplinary comprehensive review and meta-analysis","volume":"10","author":"Di Donato","year":"2022","journal-title":"Vaccines"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2021.05.012","article-title":"The efficacy of vaccination to prevent human papilloma viruses infection at anal and oral: a systematic review and meta-analysis","volume":"196","author":"Zhang","year":"2021","journal-title":"Public Health"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.934475","article-title":"Review articles, systematic reviews, meta-analysis, and the updated preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020 guidelines","volume":"27","author":"Parums","year":"2021","journal-title":"Med Sci monitor: Int Med J Exp Clin Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2399","article-title":"Efficacy, immunogenicity and safety of the AS04-HPV-16\/18 vaccine in Chinese women aged 18\u201325 years: End-of-study results from a phase II\/III, randomised, controlled trial","volume":"8","author":"Zhu","year":"2019","journal-title":"Cancer Med"},{"key":"B14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/cam4.869","article-title":"Efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine in Chinese women aged 18\u201325 years: event-triggered analysis of a randomized controlled trial","volume":"6","author":"Zhu","year":"2016","journal-title":"Cancer Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28897","article-title":"Efficacy, immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18\u201325 years: results from a randomized controlled trial","volume":"135","author":"Zhu","year":"2014","journal-title":"Int J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00435-2","article-title":"Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial","volume":"22","author":"Zhao","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/21645515.2022.2052700","article-title":"The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20\u201345 years of age","volume":"18","author":"Zhao","year":"2022","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B18","first-page":"S21","article-title":"Long-term efficacy of quadrivalent human papillomavirus vaccine in Chinese women during 10 years of follow-up","volume":"24","author":"Zhao","year":"2020","journal-title":"J lower genital tract Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30120-7","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"16","author":"Wheeler","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26362","article-title":"Efficacy of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in women aged 15\u201325 years with and without serological evidence of previous exposure to HPV-16\/18","volume":"131","author":"Szarewski","year":"2012","journal-title":"Int J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis619","article-title":"Safety and immunogenicity of human papillomavirus-16\/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women","volume":"207","author":"Sow","year":"2013","journal-title":"J Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60920-X","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"384","author":"Skinner","year":"2014","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/21645515.2023.2209001","article-title":"Safety and immunogenicity of a bivalent HPV16\/18 vaccine in Chinese females","volume":"19","author":"Shi","year":"2023","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-4104","article-title":"Randomized phase II trial of imiquimod with or without 9vHPV vs observation in patients with CIN 2 and 3","volume":"84","author":"Sheth","year":"2024","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4161\/hv.18865","article-title":"Sustained immunogenicity and efficacy of the HPV-16\/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up","volume":"8","author":"Roteli-Martins","year":"2012","journal-title":"Hum Vaccines immunotherapeutics"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz074","article-title":"Efficacy, safety, and immunogenicity of an escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial","volume":"112","author":"Qiao","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination","volume":"10","author":"Naud","year":"2014","journal-title":"Hum Vaccines immunotherapeutics"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.7.15579","article-title":"Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults","volume":"7","author":"Moreira","year":"2011","journal-title":"Hum Vaccines"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2092363","DOI":"10.1080\/21645515.2022.2092363","article-title":"Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6\/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial","volume":"18","author":"Mo","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.01.069","article-title":"Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study","volume":"37","author":"Mikamo","year":"2019","journal-title":"Vaccine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.02.079","article-title":"Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females","volume":"30","author":"Li","year":"2012","journal-title":"Vaccine"},{"key":"B34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/QAI.0b013e3181de8d26","article-title":"Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old","volume":"55","author":"Levin","year":"2010","journal-title":"J acquired Immune deficiency syndromes"},{"key":"B35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"crossref","first-page":"e015867","DOI":"10.1136\/bmjopen-2017-015867","article-title":"Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials","volume":"7","author":"Lehtinen","year":"2016","journal-title":"BMJ Open"},{"key":"B37","first-page":"5","article-title":"Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial","volume":"11","author":"Lehtinen","year":"2019","journal-title":"BMJ Open"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa011","article-title":"Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial","volume":"112","author":"Kreimer","year":"2020","journal-title":"J Natl Cancer Institute"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70213-3","article-title":"Efficacy of a bivalent HPV 16\/18 vaccine against anal HPV 16\/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial","volume":"12","author":"Kreimer","year":"2011","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/IGC.0b013e3181d373a5","article-title":"Efficacy of human papillomavirus 16\/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial","volume":"20","author":"Konno","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2010.25.8.1197","article-title":"Vaccination with a human papillomavirus (HPV)-16\/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10\u201314 years","volume":"25","author":"Kim","year":"2010","journal-title":"J Korean Med Sci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3802\/jgo.2011.22.2.67","article-title":"Human papillomavirus 16\/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15\u201325 years old healthy Korean women","volume":"22","author":"Kim","year":"2011","journal-title":"J gynecologic Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"106473","DOI":"10.1016\/j.ypmed.2021.106473","article-title":"Preterm birth rate after bivalent HPV vaccination: registry-based follow-up of a randomized clinical trial","volume":"146","author":"Kalliala","year":"2021","journal-title":"Prev Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2023.09.020","article-title":"Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6\/11\/16\/18\/31\/33\/45\/52\/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial","volume":"68","author":"Hu","year":"2023","journal-title":"Sci Bull (Beijing)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1829411","article-title":"Efficacy of the AS04-adjuvanted HPV-16\/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial","volume":"17","author":"Hu","year":"2021","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05208-11","article-title":"Immunogenicity of the quadrivalent human papillomavirus (type 6\/11\/16\/18) vaccine in males 16 to 26 years old","volume":"19","author":"Hillman","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.06.038","article-title":"Efficacy of the HPV-16\/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16\/18 vaccine trial","volume":"32","author":"Hildesheim","year":"2014","journal-title":"Vaccine"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/v13020144","article-title":"Effectiveness of the quadrivalent HPV vaccine in preventing anal \u2265 HSILs in a spanish population of HIV+ MSM aged > 26 years","volume":"13","author":"Hidalgo-Tenorio","year":"2021","journal-title":"Viruses"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0131","article-title":"Prevention of persistent human papillomavirus infection by an HPV16\/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica","volume":"1","author":"Herrero","year":"2011","journal-title":"Cancer Discov"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.06.057","article-title":"Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males","volume":"31","author":"Goldstone","year":"2013","journal-title":"Vaccine"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00327-3","article-title":"Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Goldstone","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta24470","article-title":"Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT","volume":"24","author":"Gilson","year":"2020","journal-title":"Health Technol Assess (Winchester England)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30391","article-title":"Prior human papillomavirus-16\/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: post-hoc analysis from a randomized controlled trial","volume":"139","author":"Garland","year":"2016","journal-title":"Int J Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.08.059","article-title":"Safety and immunogenicity of a 9-valent HPV vaccine in females 12\u201326 years of age who previously received the quadrivalent HPV vaccine","volume":"33","author":"Garland","year":"2015","journal-title":"Vaccine"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.09.032","article-title":"Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study","volume":"31","author":"Denny","year":"2013","journal-title":"Vaccine"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.07.007","article-title":"Sustained efficacy and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women","volume":"28","author":"De Carvalho","year":"2010","journal-title":"Vaccine"},{"key":"B57","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2018.12.030","article-title":"Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up","volume":"37","author":"Chen","year":"2019","journal-title":"Vaccine"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00591-14","article-title":"Efficacy of human papillomavirus 16 and 18 (HPV-16\/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial","volume":"22","author":"Apter","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00851-9","article-title":"An updated analysis of the impact of HPV vaccination based on long-term effectiveness in the Netherlands","volume":"12","author":"Luttjeboer","year":"2023","journal-title":"Infect Dis Ther"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2184760","DOI":"10.1080\/21645515.2023.2184760","article-title":"Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials","volume":"19","author":"Goldstone","year":"2023","journal-title":"Hum Vaccines immunotherapeutics"},{"key":"B61","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41392-024-02083-w","article-title":"Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1177\/03008916231208344","article-title":"HPV-related lesions after hysterectomy for high-grade cervical intraepithelial neoplasia and early-stage cervical cancer: a focus on the potential role of vaccination","volume":"110","author":"Bogani","year":"2024","journal-title":"Tumori J"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2239085","DOI":"10.1080\/21645515.2023.2239085","article-title":"Human papillomavirus vaccine effectiveness by age at vaccination: a systematic review","volume":"19","author":"Ellingson","year":"2023","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B64","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/pathogens12020350","article-title":"Prevalence of HPV and assessing type-specific HPV testing in cervical high-grade squamous intraepithelial lesions in Poland","volume":"12","author":"Przybylski","year":"2023","journal-title":"Pathogens"},{"key":"B65","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12967-022-03471-y","article-title":"Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st\u20132nd, 2021","volume":"20","author":"Ascierto","year":"2022","journal-title":"J Trans Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"6627531","DOI":"10.1155\/2021\/6627531","article-title":"Progression of CIN1\/LSIL HPV persistent of the cervix: actual progression or CIN3 coexistence","volume":"2021","author":"Bruno","year":"2021","journal-title":"Infect Dis obstetrics gynecology"},{"key":"B67","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-02200-6_18","article-title":"Biological pathways of HPV-induced carcinogenesis","author":"Don\u00e0","year":"2020","journal-title":"Sexually Transmitted Infections: Adv Understanding Manage"},{"key":"B68","doi-asserted-by":"publisher","first-page":"102467","DOI":"10.1016\/j.ctrv.2022.102467","article-title":"HPV vaccination and HPV-related Malignancies: impact, strategies and optimizations toward global immunization coverage","volume":"111","author":"Giannone","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12650","article-title":"The crossroads: divergent roles of virus-specific CD4+ T lymphocytes in determining the outcome for human papillomavirus infection","volume":"101","author":"van Bockel","year":"2023","journal-title":"Immunol Cell Biol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2022.2021077","article-title":"Progression from human papillomavirus (HPV) infection to cervical lesion or clearance in women (18\u201325 years): natural history study in the control arm subjects of AS04-HPV-16\/18 vaccine efficacy study in China between 2008 and 2016","volume":"21","author":"Welby","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"New Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1471-2334-13-75","article-title":"Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands","volume":"13","author":"Westra","year":"2013","journal-title":"BMC Infect Dis"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1520591","article-title":"HPV vaccination acceptability among men who have sex with men in Urumqi, China","volume":"15","author":"Tian","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30873-2","article-title":"Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials","volume":"21","author":"Mariz","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3390\/vaccines9050442","article-title":"Differential antibody response against conformational and linear epitopes of the L1 proteins from human papillomavirus types 16\/18 is observed in vaccinated women or with uterine cervical lesions","volume":"9","author":"Pedroza-Saavedra","year":"2021","journal-title":"Vaccines"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.2174\/187152061402140128163306","article-title":"HPV-specific immunotherapy: key role for immunomodulators","volume":"14","author":"Van de Wall","year":"2014","journal-title":"Anti-Cancer Agents Medicinal Chemistry-Anti-Cancer Agents)"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.3390\/vaccines11111704","article-title":"Advancements in vaccine adjuvants: the journey from alum to nano formulations","volume":"11","author":"Moni","year":"2023","journal-title":"Vaccines"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1936860","article-title":"The impact of HPV vaccination beyond cancer prevention: effect on pregnancy outcomes","volume":"17","author":"Yuill","year":"2021","journal-title":"Hum Vaccines immunotherapeutics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1747082\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:35:11Z","timestamp":1768286111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1747082\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":78,"alternative-id":["10.3389\/fimmu.2025.1747082"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1747082","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"article-number":"1747082"}}